---
title: "Interpretable biomarker programs predict treatment response in lupus nephritis across four regimens"
id: "medrxiv-3-interpretable-biomarker-programs-predict-treatment-response-in-lupus-nephritis"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-3-interpretable-biomarker-programs-predict-treatment-response-in-lupus-nephritis"
content_type: "clinical_feed_article"
specialty: "Nephrology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1?rss=1"
published_at: "2026-09-15T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Interpretable biomarker programs predict treatment response in lupus nephritis across four regimens
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-3-interpretable-biomarker-programs-predict-treatment-response-in-lupus-nephritis
- **Specialty:** [Nephrology](https://medichelpline.com/clinical-feed/nephrology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1?rss=1)
- **Published At:** 2026-09-15T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study applied interpretable machine learning to gene-expression data from a lupus nephritis treatment-response cohort (GSE224705) with 21,914 genes across 319 samples to derive multi-gene programs that separate responders from non-responders within each treatment group. - Four regimens were analysed: **mycophenolate mofetil (MMF)**, **azathioprine (AZA)**, **hydroxychloroquine (HC)**, and standard of care (SOC). - Compact programs of five to ten genes achieved high patient-level discrimination for MMF (AUROC 0.847) and AZA (AUROC 0.866), while HC (AUROC 0.718) and SOC (AUROC 0.623) performed worse; SOC models were near chance (MCC 0.119, balanced accuracy 0.555). - The regimen-specific discriminability indicates some therapies have clear transcriptional response signals while others do not; lack of transcriptional separation is actionable for trial design rather than necessarily indicating therapeutic failure. - Reconstructed counts of significant differentially expressed genes differed markedly from the published analysis (for example, 222 vs. 46 for MMF and 4,455 vs. 157 for AZA), but the dominant biology and predictive performance of programs were preserved. - Programs were non-redundant: removal of a single gene (TUBB2A) from the MMF program reduced AUROC by ~0.17, indicating individual genes can be important to predictive performance. - At the pathway level, 13 cross-treatment enrichment relationships remained significant after adjustment, suggesting treatment-specific response landscapes that are nevertheless coupled across regimens. - The authors propose that patient-generalisable biomarker programs could enable enrichment-style trial design by identifying likely responders before enrolment, and caution that the raw count of differentially expressed genes is a poor proxy for signal strength or stability. - Data and code provenance: bulk data are publicly available at GEO accession GSE224705 and BioProject PRJNA932236; original analysis code repositories were cited and reconstructed materials will be deposited on publication. - Authors declared no competing interests and confirmed appropriate ethical approvals and participant consent; details and code links were provided in the source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=PW6FiOwndwHSM8cGTYxperKp06j.VdVA4RqeterHqdU-1789486604.490332-1.2.1.1-kmghChWD9NWQ8LD.PFofIN9JG08CdbOX0DbfjebysB1g84d0oAPZyR4BjHsA8IrB) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Interpretable biomarker programs predict treatment response in lupus nephritis: patient-level validation across four regimens [ View ORCID Profile](http://orcid.org/0009-0008-6794-626X)Prashant Kumar, Abhinav Aurange, Swapnil Keshari, Shreyan Nalwad doi: https://doi.org/10.64898/2026.09.13.26362948 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Prashant Kumar Phaseo AI * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Prashant%2BKumar%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kumar%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APrashant%2BKumar%2B) * [ORCID record for Prashant Kumar](http://orcid.org/0009-0008-6794-626X "Open in new tab") * For correspondence: kumarp79584@gmail.com Abhinav Aurange Phaseo AI * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Abhinav%2BAurange%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Aurange%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAbhinav%2BAurange%2B) Swapnil Keshari Phaseo AI * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Swapnil%2BKeshari%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Keshari%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASwapnil%2BKeshari%2B) Shreyan Nalwad Phaseo AI * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shreyan%2BNalwad%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nalwad%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShreyan%2BNalwad%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1300321/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1300321/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1300321/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1300321/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1300321/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1300321/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract A large share of late-stage clinical trial failures reflects not the underlying biology of the target but the composition of the enrolled population: trials recruit patients in whom the drug cannot work. Methods that identify likely responders before treatment therefore address a failure mode that better target selection alone cannot. We applied interpretable machine learning to gene-expression data from a treatment-response cohort in lupus nephritis (GSE224705; 21,914 genes across 319 samples) covering four regimens: mycophenolate mofetil (MMF), azathioprine (AZA), hydroxychloroquine (HC) and standard of care (SOC). We independently reconstructed the expression matrix and metadata, rebuilt the treatment-specific cohorts, and derived compact multi-gene programs that separate responders from non-responders within each treated population. Two results follow. First, discriminative performance is strongly graded by regimen. Com pact programs of five to ten genes achieved patient-level AUROC of 0.847 (MMF) and 0.866 (AZA), but only 0.718 (HC) and 0.623 (SOC); the SOC programs performed close to chance (MCC 0.119, balanced accuracy 0.555). A regimen in which response is not transcriptionally discriminable is an actionable finding for trial design rather than a null result. Second, the programs proved considerably more stable than the differential-expression lists that generated them: reconstructed counts of significant genes differed markedly from the published analysis (222 vs. 46 for MMF; 4,455 vs. 157 for AZA; 6 vs. 24 for HC; 5 vs. 11 for SOC), yet the dominant biology and the predictive performance were preserved. Programs were also non-redundant: re moving a single gene (TUBB2A) from the MMF program reduced AUROC by approximately 0.17. At the pathway level, 13 cross-treatment enrichment relationships remained significant after adjustment, indicating that response landscapes are treatment-specific yet coupled. Patient-generalisable programs of this kind offer a concrete near-term route to enrichment style trial design, identifying before enrolment which patients a given therapy suits. Our results also caution that the number of differentially expressed genes is a poor proxy for the strength or stability of a response signal. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Bulk expression and clinical data are available at GEO accession GSE224705 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE224705) and BioProject PRJNA932236. The original study analysis code is available at https://github.com/dtordom/LNtherapy and https://github.com/jordimartorell/pathMED. Reconstructed expression and metadata objects, per regimen differential expression results, the complete analysis history and figure-generation code will be deposited on publication I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The bulk expression and clinical data analysed in this study are publicly available from the Gene Expression Omnibus (GEO) under accession GSE224705 and BioProject PRJNA932236. The original study analysis code is available at the repositories cited in the manuscript. The reconstructed expression and metadata objects, per-regimen differential expression results, complete analysis history, and figure-generation code will be deposited on publication Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.12.26362914v1 "Cardiometabolic Risk Trajectories in Young Adults Across 16 Middle East and North African Countries, 1990-2018: A Sex-Asymmetric Divergence") Posted September 15, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/15/2026.09.13.26362948.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.13.26362948v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/15/2026.09.13.26362948.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Interpretable biomarker programs predict treatment response in lupus nephritis: patient-level validation across four regimens Prashant Kumar, Abhinav Aurange, Swapnil Keshari, Shreyan Nalwad medRxiv 2026.09.13.26362948; doi: https://doi.org/10.64898/2026.09.13.26362948 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.13.26362948v1%26text%3DInterpretable%2520biomarker%2520programs%2520predict%2520treatment%2520response%2520in%2520lupus%2520nephritis%253A%2520patient-level%2520validation%2520across%2520four%2520regimens "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.13.26362948v1%26t%3DInterpretable%2520biomarker%2520programs%2520predict%2520treatment%2520response%2520in%2520lupus%2520nephritis%253A%2520patient-level%2520validation%2520across%2520four%2520regimens "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.13.26362948v1%26title%3DInterpretable%2520biomarker%2520programs%2520predict%2520treatment%2520response%2520in%2520lupus%2520nephritis%253A%2520patient-level%2520validation%2520across%2520four%2520regimens%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.13.26362948v1%26title%3DInterpretable%2520biomarker%2520programs%2520predict%2520treatment%2520response%2520in%2520lupus%2520nephritis%253A%2520patient-level%2520validation%2520across%2520four%2520regimens "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.13.26362948) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.13.26362948v1&count=horizontal&via=&text=Interpretable%20biomarker%20programs%20predict%20treatment%20response%20in%20lupus%20nephritis%3A%20patient-level%20validation%20across%20four%20regimens&counturl=www.medrxiv.org/content/10.64898/2026.09.13.26362948v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (617) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (901) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (331) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4810) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (479) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (415) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (648) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1626) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15938) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1202) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7044) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (733) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1064) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5043) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1434) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1763) * [Hematology](https://www.medrxiv.org/collection/hematology) (585) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1344) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16289) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1173) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (668) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (154) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (722) * [Neurology](https://www.medrxiv.org/collection/neurology) (7271) * [Nursing](https://www.medrxiv.org/collection/nursing) (366) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1081) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1241) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1005) * [Oncology](https://www.medrxiv.org/collection/oncology) (3607) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1051) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (397) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (454) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (470) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (707) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1798) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (737) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (766) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5891) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9750) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2420) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1450) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1248) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (640) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (771) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (578) * [Surgery](https://www.medrxiv.org/collection/surgery) (776) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (305) * [Urology](https://www.medrxiv.org/collection/urology) (291) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of
## Related Clinical Research

- [Telitacicept for Lupus Nephritis: Real‑World Triple‑Cohort Study — Article Content Not Available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-real-world-triple-cohort-study-on-the-effectiveness-and-safety-of.md)
- [Blood urea nitrogen–to–albumin ratio (BAR) and kidney stones: cross-sectional NHANES analysis](https://medichelpline.com/clinical-feed/medrxiv-4-association-between-blood-urea-nitrogen-to-albumin-ratio-and-kidney-stones-a.md)
- [Hepatitis E Virus IgG Seropositivity and Kidney Dysfunction in US Adults](https://medichelpline.com/clinical-feed/medrxiv-3-hepatitis-e-virus-immunoglobulin-g-seropositivity-and-kidney-dysfunction-among.md)
- [Procoagulant effects of extracellular vesicles in patients with livedo reticularis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-procoagulant-effects-of-extracellular-vesicles-in-patients-with-livedo.md)
- [Barriers to Primary Healthcare for the Rural Bangladeshi Elderly: A Social Ecological Model Review](https://medichelpline.com/clinical-feed/plos-one-19-using-the-social-ecological-model-to-identify-barriers-to-accessing-and-using.md)

## Navigation
- [← Back to Nephrology Feed](https://medichelpline.com/clinical-feed/nephrology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.